:
Recursion Pharmaceuticals, a clinical-stage technology-driven drug discovery company, announced key advancements in its drug development pipeline and corporate partnerships. Notably, the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader aimed at treating biomarker-enriched solid tumors and lymphoma. Simultaneously, Recursion has entered into a definitive agreement with Exscientia to enhance drug discovery efficiencies, anticipated to generate annual synergies of approximately $100 million. Additionally, research findings published in Nature Genetics underscore the company’s capabilities in genomic studies, illuminating potential limitations of CRISPR gene editing technologies.
The pharmaceutical industry is continuously evolving as new technologies and approaches enrich drug discovery and development. Recently, Recursion Pharmaceuticals has leveraged its innovative platforms to secure FDA clearance for a promising new therapeutic and strengthen its operational capacity through strategic partnerships.
FDA Clearance for REC-1245
On October 2, 2024, Recursion Pharmaceuticals announced that the FDA granted clearance for the IND application pertaining to REC-1245. This novel chemical entity is positioned as a potential first-in-class RBM39 degrader, targeting solid tumors and lymphomas characterized by specific biomarkers. The Phase 1/2 clinical trial will further evaluate REC-1245’s safety and efficacy, addressing a critical need in oncology for targeted therapies catering to biomarker-specific populations.
Partnership with Exscientia
In conjunction with its drug development initiatives, Recursion has finalized a strategic partnership with Exscientia, a leader in AI-driven drug design. This collaboration aims to create a global technology-enabled drug discovery leader, harnessing operational complementarities and expertise from both organizations. The alliance is expected to yield annual synergies of approximately $100 million, enhancing the efficiency and effectiveness of the drug discovery process through integrated technological advancements.
Advancements in Gene Editing Research
In a further demonstration of its innovative capabilities, Recursion has contributed to the study of CRISPR gene editing technologies. A paper published open-access in ’Nature Genetics’ highlights the findings from high-resolution genome-wide mapping that elucidates novel evidence of proximity bias in CRISPR-Cas9 gene knockouts. This work not only critiques the efficacy of existing CRISPR methodologies but also proposes a debiasing algorithm, marking a significant contribution to the genomic editing field.
Conclusion:
Recursion Pharmaceuticals is poised for strategic growth and innovation in drug development as evidenced by the recent FDA clearance of REC-1245 and its partnership with Exscientia. These advancements, combined with ongoing research in gene editing technologies, position Recursion as a key player in the biotechnology landscape, addressing critical therapeutic needs in oncology and enhancing the drug discovery pipeline.
Keywords: Recursion Pharmaceuticals, FDA clearance, REC-1245, RBM39 degrader, Exscientia partnership, gene editing, CRISPR.
Comments